MPT · Medical Properties Trust Inc
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 10, 2026TL;DR. MPT announced a $2.4 billion 9.25% secured refinancing that eliminates 2026 maturities and materially reduces 2027 unsecured maturities, with no debt due until June 2028; portfolio coverage remains broadly stable with post-acute EBITDA up over $70 million YoY and NFFO of $0.15 in line with expectations, while behavioral health coverage slipped to 1.4x and U.K. NHS funding pressure persists.
- + Announced $2.4 billion refinancing extends $2.4 billion of debt maturities to 2032 with no debt maturing in 2026 or 2027.
- + Refinancing reduces total principal debt by approximately $123 million and substantially increases UA/UD covenant headroom to up to nearly 300%.
- + Post-acute portfolio EBITDA increased more than $70 million YoY, led by 24% growth in Median and 13% in Ernest Health, with 2.4x coverage.
- + Asset sales validate market values materially above book, including a pending $172 million sale at a 60%+ gain over original investment and 34% IRR.
- − Behavioral health coverage slipped to 1.4x due to U.K. NHS funding pressures and is a source of pressure on the overall portfolio.
- − HSA cash collections remain below target (still in the 80s), with a Meditech EMR conversion, RCM outsourcing disruption, and delayed Florida supplemental funding pressuring liquidity.
- − Secured debt ratio is rising to near the 40% covenant ceiling, limiting additional secured-debt capacity absent asset sales.
- − Company impaired approximately $17 million in working capital loans tied to Steward replacement tenants in the Midwest.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| countries | 9 | Q2 2026 | — |
| facilities | 373 | as of June 30, 2026 | — |
| Funds from operations non-GAAP | 207.37M | Six Months Ended June 30, 2026 | — |
| licensed beds | 38,000 | as of June 30, 2026 | — |
| Normalized funds from operations non-GAAP | 174.46M | For the Six Months Ended June 30, 2026 | — |
| Normalized Funds from Operations (NFFO) non-GAAP | 92M | second quarter ended June 30, 2026 | — |
| Normalized funds from operations per diluted share non-GAAP | $0.29 | For the Six Months Ended June 30, 2026 | — |
| operators | 51 | Q2 2026 | — |
| U.S. states | 30 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
REIT - Healthcare Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MPT
this stock
Medical Properties Trust Inc
|
$1.70B | -43.0% | -2.4% | — | 24.4% |
|
WELL
Welltower Inc.
|
$168.32B | +25.8% | +35.6% | 109.9 | 2.5% |
|
VTR
Ventas, Inc.
|
$44.28B | +9.2% | +18.5% | 159.9 | 3.2% |
|
OHI
Omega Healthcare Investors Inc
|
$13.60B | +1.2% | +13.2% | 16.0 | 5.2% |
|
DOC
Healthpeak Properties, Inc.
|
$12.69B | +14.4% | +4.5% | 52.6 | 3.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MPT | -9.2% | -21.9% | -44.9% | -17.6% | -43.0% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -7.8% | -21.0% | -52.6% | -18.1% | -55.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.